Boehringer Ingelheim is investing again in immuno-oncology, announcing Monday a deal to acquire the San Diego-based biotechnology startup Nerio Therapeutics and its slate of preclinical drug ...

Boehringer Ingelheim announced it will buy Nerio Therapeutics for $1.3 billion Monday morning. The German drugmaker is bolstering its immuno-oncology pipeline by adding the San Diego-based drug ...

Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline as the company is adding an innovative preclinical program with the acquisition of Nerio Therapeutics Inc. (“Nerio”) ...

Boehringer Ingelheim is offering up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece ...

Nerio’s candidates have yet to be tested in humans. According to securities filings, the start-up, based in La Jolla, California, had previously raised about $6.5 million in venture funding.